Adnexus Therapeutics

Compound Therapeutics Announces Initiation of IND-Enabling Safety Studies with Lead Oncology Product

Compound Therapeutics Announces Initiation of IND-Enabling Safety Studies with Lead Oncology Product

June 22, 2005

First of a New Class of Protein Therapeutics

Waltham, MA, June 22, 2005 -- Compound Therapeutics announced that it has initiated IND-enabling animal safety studies with CT-322, its lead product. CT-322 is an AdNectin blocker of vascular endothelial growth factor receptor-2 (VEGFR-2), a receptor that is the key driver of angiogenesis. Inhibition of this biological pathway has been demonstrated to be highly effective in treating many cancers, as well as in treating age-related macular degeneration (AMD).

Zalicus

CombinatoRx Licenses CRx-026 Territory Right to HenKan

CombinatoRx Licenses CRx-026 Territory Right to HenKan

July 18, 2005

Partnership Accelerates Development and Commercialization of CRx-026 in Taiwan, China and South Korea

BOSTON, MA and TAIPEI, TAIWAN -- July 18, 2005 - CombinatoRx, Incorporated, a privately held biopharmaceutical company, and HenKan Pharmaceutical Company today announced the signing of a territorial license agreement for CRx-026, a novel dual action anti-cancer agent in clinical development for solid tumors.

BG Medicine, Inc.

BG Medicine Announces Agreement with Boehringer Ingelheim Pharmaceuticals, Inc.

BG Medicine Announces Agreement with Boehringer Ingelheim Pharmaceuticals, Inc.

July 28, 2005

WALTHAM, Mass.--(BUSINESS WIRE)--July 28, 2005--BG Medicine announced today that it has entered into an agreement with Boehringer Ingelheim Pharmaceuticals, Inc. BG Medicine will apply its Systems Pharmacology platform to elucidate tissue drug effects and discover circulating biomarkers for clinical application. BG Medicine will take a systems biology approach employing multiple platforms to generate data for analyses in proprietary bioinformatics and statistical methods. Financial terms of the agreement were not disclosed.

VisEn Medical, Inc.

VisEn Medical Announces $4M Venture Capital Financing

VisEn Medical Announces $4M Venture Capital Financing

August 15, 2005

CAMBRIDGE, Mass., Aug. 15 /PRNewswire/ -- VisEn Medical, a pioneer in the field of optical molecular imaging, today announced that it has raised $4 million of additional venture capital financing. The round was led by Flagship Ventures and included follow-on investments by Bollard Group and other existing investors. VisEn intends to use the proceeds to support the commercial launch of its initial products later this year, and to develop additional applications of its technologies.

Ensemble Therapeutics Corporation

Ensemble Discovery Appoints Jean Jacques Bienaime to its Board of Directors

Ensemble Discovery Appoints Jean Jacques Bienaime to its Board of Directors

August 30, 2005

Cambridge, Mass., (August 30, 2005) -- Ensemble Discovery Corporation today announced the appointment of Jean-Jacques Bienaime to its Board of Directors. Mr. Bienaime is currently the Chief Executive Officer of BioMarin Pharmaceuticals Inc.

VisEn Medical, Inc.

VisEn Medical Announces the Launch of an Industry-First FMT Imaging System and Optical Probe Product Line

VisEn Medical Announces the Launch of an Industry-First FMT Imaging System and Optical Probe Product Line

September 2, 2005

Backed by 18 Abstracts at the 4th Annual Meeting of the Society For Molecular Imaging

New digs, direction for BG Medicine

New digs, direction for BG Medicine

September 13, 2005

Mass High Tech Online
09/12/2005 08:26 AM
By Dyke Hendrickson


BG Medicine Inc. moved recently into larger headquarters in Waltham -- a larger space to accommodate a big idea.

Epitome Biosystems

Epitome Biosystems to Develop Multiplex Assay Reagents for EMD Biosciences

Epitome Biosystems to Develop Multiplex Assay Reagents for EMD Biosciences

September 14, 2005

WALTHAM, Mass., Sept. 14 /PRNewswire/ -- Epitome Biosystems announced today that it has signed a licensing and development agreement with EMD Biosciences for products based on Epitome's proprietary EpiTag(TM) technology. Specifically, Epitome will develop reagents for the quantitative measurement of key intracellular signaling proteins. The companies will collaborate on development and the products will be marketed and sold for research applications on a world-wide basis by EMD Biosciences under its well-known Novagen(R) and Calbiochem(R) brands.

IntelliVid

Department Store Selects IntelliVid's Intelligent Video Analysis Solution for Loss Prevention

Department Store Selects IntelliVid's Intelligent Video Analysis Solution for Loss Prevention

September 26, 2005

CAMBRIDGE -- IntelliVid Corporation, the leader in intelligent video analysis software for retail loss prevention, today announced that a leading fashion-oriented department store has chosen its Video Investigator™ software to transform the retailer's existing closed-circuit television (CCTV) systems into a solution that enhances the shopping environment and pro-actively reduces inventory losses.

Pervasis Therapeutics, Inc.

Pervasis Therapeutics Closes $12 Million Series B Financing

Pervasis Therapeutics Closes $12 Million Series B Financing

September 30, 2005

Cell Therapy Company Developing Next-Generation Combination Treatments